UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
Study for Patients with Type 1 Diabetes To Compare Safety, Effectiveness, and Tolerability of New More Concentrated Form of Insulin Glargine

A 6-Month, Multicenter, Randomized, Open Label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period

Adults with type 1 diabetes are invited to participate in a research study to compare the safety, effectiveness, & tolerability of new more concentrated form of insulin glargine with the currently marketed form known as Lantus® in adults with type 1 diabetes.    There are 10 on-site study visits over an approximate 12 month period. 

Start Date
February 8, 2013
End Date
March 1, 2014
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Eva Tsalikian, MD
Contact Info

Julie Coffey at 319-353-6070 or julie-coffey@uiowa.edu

type 1 diabetes+adult+ U-300 ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.